Ultragenyx (RARE) Stock Analysis

Ultragenyx (RARE) is a publicly traded company in the HEALTHCARE sector. It trades at $21.78, carries a market capitalization of $2.25B. This page summarizes the public market data, fundamentals, and frequently asked questions for RARE, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $21.78
• Market Cap: $2.25B
• EPS: $-6.10
• 52-Week High: $42.37
• 52-Week Low: $18.29

Market Sentiment

Ultragenyx currently has a Bearish sentiment score of -0.37.

About Ultragenyx

Ultragenyx Pharmaceutical Inc. (RARE) is a leading biopharmaceutical firm dedicated to the advancement of innovative therapies for patients suffering from rare and ultra-rare genetic disorders. With its headquarters in Novato, California, the company is committed to addressing significant unmet medical needs through a robust pipeline of product candidates, which includes both gene therapy and enzyme replacement therapies. Ultragenyx employs a patient-centric approach, ensuring that the develo...

GNG Research Analysis

GNG Research scores Ultragenyx (RARE) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for RARE.

Frequently Asked Questions

Does RARE pay dividends?

Ultragenyx (RARE) does not currently pay a regular dividend.

What is RARE's market cap?

Ultragenyx (RARE) has a market capitalization of $2.25B with a current stock price of $21.78.